Drug Profile
Epratuzumab I-131
Alternative Names: Anti-CD22 monoclonal antibody LL2-I-131; IMMU LL2-I-131; ImmuRAIT-LL2-I -131; LymphoCide I -131; Monoclonal antibody LL2-I-131Latest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Immunomedics
- Developer Immunomedics; Repligen Corporation
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 08 Aug 2001 US patent issued to Immunomedics covering the engineering of a glycosylation site on anti-CD22 antibodies for the purpose of attaching drugs or isotopes without affecting targeting
- 24 Feb 2000 A phase I study in non-Hodgkin's lymphoma has been added to the therapeutic trials section